Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial
Importance Interleukin 13 (IL-13) is a central pathogenic mediator driving multiple features of
atopic dermatitis (AD) pathophysiology. Objective To evaluate the efficacy and safety of
lebrikizumab, a novel, high-affinity, monoclonal antibody targeting IL-13 that selectively
prevents formation of the IL-13Rα1/IL-4Rα heterodimer receptor signaling complex, in adults
with moderate to severe AD. Design, Setting, and Participants A phase 2b, double-blind,
placebo-controlled, dose-ranging randomized clinical trial of lebrikizumab injections every 4 …
atopic dermatitis (AD) pathophysiology. Objective To evaluate the efficacy and safety of
lebrikizumab, a novel, high-affinity, monoclonal antibody targeting IL-13 that selectively
prevents formation of the IL-13Rα1/IL-4Rα heterodimer receptor signaling complex, in adults
with moderate to severe AD. Design, Setting, and Participants A phase 2b, double-blind,
placebo-controlled, dose-ranging randomized clinical trial of lebrikizumab injections every 4 …